156 related articles for article (PubMed ID: 36581736)
1. DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression.
Kong T; Laranjeira ABA; Yang K; Fisher DAC; Yu L; Poittevin De La Frégonnière L; Wang AZ; Ruzinova MB; Fowles JS; Fulbright MC; Cox MJ; Celik H; Challen GA; Huang S; Oh ST
Nat Cancer; 2023 Jan; 4(1):108-127. PubMed ID: 36581736
[TBL] [Abstract][Full Text] [Related]
2. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
3. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic JAK2
Prestipino A; Emhardt AJ; Aumann K; O'Sullivan D; Gorantla SP; Duquesne S; Melchinger W; Braun L; Vuckovic S; Boerries M; Busch H; Halbach S; Pennisi S; Poggio T; Apostolova P; Veratti P; Hettich M; Niedermann G; Bartholomä M; Shoumariyeh K; Jutzi JS; Wehrle J; Dierks C; Becker H; Schmitt-Graeff A; Follo M; Pfeifer D; Rohr J; Fuchs S; Ehl S; Hartl FA; Minguet S; Miething C; Heidel FH; Kröger N; Triviai I; Brummer T; Finke J; Illert AL; Ruggiero E; Bonini C; Duyster J; Pahl HL; Lane SW; Hill GR; Blazar BR; von Bubnoff N; Pearce EL; Zeiser R
Sci Transl Med; 2018 Feb; 10(429):. PubMed ID: 29467301
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
[TBL] [Abstract][Full Text] [Related]
6. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
7. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.
Wolach O; Sellar RS; Martinod K; Cherpokova D; McConkey M; Chappell RJ; Silver AJ; Adams D; Castellano CA; Schneider RK; Padera RF; DeAngelo DJ; Wadleigh M; Steensma DP; Galinsky I; Stone RM; Genovese G; McCarroll SA; Iliadou B; Hultman C; Neuberg D; Mullally A; Wagner DD; Ebert BL
Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643232
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
Bhagwat N; Levine RL; Koppikar P
Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
[TBL] [Abstract][Full Text] [Related]
9. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
10. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O
PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189
[TBL] [Abstract][Full Text] [Related]
11. JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.
Irino T; Uemura M; Yamane H; Umemura S; Utsumi T; Kakazu N; Shirakawa T; Ito M; Suzuki T; Kinoshita K
PLoS One; 2011; 6(7):e22148. PubMed ID: 21789226
[TBL] [Abstract][Full Text] [Related]
12. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
13. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
Lee HJ; Daver N; Kantarjian HM; Verstovsek S; Ravandi F
Clin Cancer Res; 2013 Jan; 19(2):327-35. PubMed ID: 23209034
[TBL] [Abstract][Full Text] [Related]
14. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
Rampal R; Al-Shahrour F; Abdel-Wahab O; Patel JP; Brunel JP; Mermel CH; Bass AJ; Pretz J; Ahn J; Hricik T; Kilpivaara O; Wadleigh M; Busque L; Gilliland DG; Golub TR; Ebert BL; Levine RL
Blood; 2014 May; 123(22):e123-33. PubMed ID: 24740812
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
Gurska LM; Okabe R; Schurer A; Tong MM; Soto M; Choi D; Ames K; Glushakow-Smith S; Montoya A; Tein E; Miles LA; Cheng H; Hankey-Giblin P; Levine RL; Goel S; Halmos B; Gritsman K
Clin Cancer Res; 2023 Mar; 29(5):943-956. PubMed ID: 36537918
[TBL] [Abstract][Full Text] [Related]
16. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
[TBL] [Abstract][Full Text] [Related]
17. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
18. JAK2 the future: therapeutic strategies for JAK-dependent malignancies.
LaFave LM; Levine RL
Trends Pharmacol Sci; 2012 Nov; 33(11):574-82. PubMed ID: 22995223
[TBL] [Abstract][Full Text] [Related]
19. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
Koppikar P; Bhagwat N; Kilpivaara O; Manshouri T; Adli M; Hricik T; Liu F; Saunders LM; Mullally A; Abdel-Wahab O; Leung L; Weinstein A; Marubayashi S; Goel A; Gönen M; Estrov Z; Ebert BL; Chiosis G; Nimer SD; Bernstein BE; Verstovsek S; Levine RL
Nature; 2012 Sep; 489(7414):155-9. PubMed ID: 22820254
[TBL] [Abstract][Full Text] [Related]
20. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.
Fleischman AG; Aichberger KJ; Luty SB; Bumm TG; Petersen CL; Doratotaj S; Vasudevan KB; LaTocha DH; Yang F; Press RD; Loriaux MM; Pahl HL; Silver RT; Agarwal A; O'Hare T; Druker BJ; Bagby GC; Deininger MW
Blood; 2011 Dec; 118(24):6392-8. PubMed ID: 21860020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
